Quick Answer
Apimeds Pharmaceuticals US, Inc. reported Total Assets of $13.1 thousand for fiscal year 2024.
Apimeds Pharmaceuticals US, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2024 | $13.1K | -96.9% |
| 2023 | $422.1K | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.25M | — | -12.3% |
| June 30, 2025 | $10.55M | — | +3957.9% |
| March 31, 2025 | $259.9K | — | +1890.5% |
| December 31, 2024 | $13.1K | — | — |
- Apimeds Pharmaceuticals US, Inc. showed a decrease of -96.9% in Total Assets compared to the prior fiscal year.
- Over the 2023–2024 period, Apimeds Pharmaceuticals US, Inc.’s total assets has declined by 96.9% (from $422.1 thousand to $13.1 thousand).
- The most recent figure is from Apimeds Pharmaceuticals US, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: